Company Description
Bullfrog AI Holdings, Inc., through its subsidiaries, operates as a digital biopharmaceutical company that focuses on artificial intelligence and machine learning (AI/ML) driven analysis of data sets in medicine and healthcare in the United States.
The company offers bfLEAP, an analytical AI/ML platform for the analysis of preclinical and/or clinical data.
It also has licensing agreements with George Washington University for rights to use siRNA targeting Beta2-spectrin in the treatment of human diseases, including hepatocellular carcinoma, obesity, non-alcoholic fatty liver disease, and non-alcoholic steatohepatitis; and Johns Hopkins University for the use of a formulation of Mebendazole for the treatment of glioblastoma, and human cancer or neoplastic disease.
The company was founded in 2017 and is based in Gaithersburg, Maryland.
| Country | United States |
| Founded | 2017 |
| IPO Date | Feb 14, 2023 |
| Industry | Health Information Services |
| Sector | Healthcare |
| Employees | 11 |
| CEO | Vininder Singh |
Contact Details
Address: 325 Ellington Boulevard, Unit 317 Gaithersburg, Maryland 20878 United States | |
| Phone | 240 658 6710 |
| Website | bullfrogai.com |
Stock Details
| Ticker Symbol | BFRG |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $6.50 |
| CIK Code | 0001829247 |
| ISIN Number | US12021E1091 |
| Employer ID | 84-4786155 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Vininder Singh | Founder, Chairman and Chief Executive Officer |
| Dane R. Saglio | Chief Financial Officer |
| J. T. Koffenberger | Chief Information Officer |
| Hon. Thomas W. Chittenden X, DPHIL, Ph.D. | Chief Scientific Officer |
| Dr. Cetin Savkli Ph.D. | Chief AI Advisor and Member of Advisory Board |
| Dr. David P. Recker FACP, FACR, M.D. | Chief Medical Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 21, 2024 | 8-K | Current Report |
| Oct 21, 2024 | 424B5 | Filing |
| Oct 15, 2024 | 8-K | Current Report |
| Oct 9, 2024 | 8-K | Current Report |
| Oct 3, 2024 | 144 | Filing |
| Sep 25, 2024 | 8-K | Current Report |
| Aug 21, 2024 | EFFECT | Notice of Effectiveness |
| Aug 15, 2024 | S-3/A | [Amend] Registration statement under Securities Act of 1933 |
| Aug 13, 2024 | UPLOAD | Filing |
| Aug 8, 2024 | DEF 14A | Other definitive proxy statements |